Premium
Anti‐Oxidative Therapy with Oral Dapsone Improved HCV Antibody Positive Annular Elastolytic Giant Cell Granuloma
Author(s) -
Igawa Ken,
Maruyama Ryuji,
Katayama Ichiro,
Nishioka Kiyoshi
Publication year - 1997
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1997.tb02799.x
Subject(s) - dapsone , medicine , granulomatous disease , cryotherapy , granuloma , giant cell , refractory (planetary science) , infiltration (hvac) , pathology , antibody , dermatology , immunology , surgery , disease , physics , astrobiology , thermodynamics
A 72‐year‐old fisherman who was positive for the HCV antibody developed an annular, erythematous, infiltrated lesions on sun‐exposed areas. The lesions were diagnosed as annular elastolytic giant cell granuloma both clinically and histologically. Topical corticosteroid and cryotherapy with liquid nitrogen for several months failed to improve the lesions. We then started dapsone, a known anti‐oxidant, at 50 mg/day. A month later, the margins of the erythematous lesions faded, and the infiltration gradually decreased. No recurrence has been observed for one year after the start of the therapy. Anti‐oxidative therapy appears to be effective for annular elastolytic giant cell granuloma and could be an alternate therapy for refractory granulomatous disease.